Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HYPRNYSE:MLSSNASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$0.14+2.7%$0.26$0.17▼$2.94$2.83M0.513.14 million shs230,539 shsHYPRHyperfine$0.69-0.7%$1.03$0.64▼$1.90$51.76M0.94372,147 shs288,694 shsMLSSMilestone Scientific$0.90-2.2%$1.08$0.54▼$1.39$70.10M1.41135,220 shs37,862 shsTELATELA Bio$1.02-12.8%$2.30$1.02▼$6.50$40.18M0.98233,405 shs1.46 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell+4.60%-22.41%-33.05%-78.73%-95.06%HYPRHyperfine-6.01%-11.15%-25.72%-34.83%-30.92%MLSSMilestone Scientific-7.07%-14.81%-17.12%-3.16%+45.99%TELATELA Bio-6.40%-14.60%-50.00%-59.79%-77.92%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine3.0687 of 5 stars3.35.00.00.01.12.51.3MLSSMilestone Scientific1.713 of 5 stars3.50.00.00.02.31.70.0TELATELA Bio2.3857 of 5 stars3.44.00.00.01.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.3393.88% UpsideMLSSMilestone Scientific 3.00Buy$1.2538.89% UpsideTELATELA Bio 2.75Moderate Buy$7.25610.78% UpsideCurrent Analyst Ratings BreakdownLatest CTCX, TELA, HYPR, and MLSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.503/21/2025TELATELA BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.003/21/2025TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$5.00 ➝ $2.003/20/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.50 ➝ $1.203/18/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$1.10 ➝ $1.29(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K86.19N/AN/A$1.07 per share0.13HYPRHyperfine$12.89M4.14N/AN/A$1.17 per share0.59MLSSMilestone Scientific$8.88M7.90N/AN/A$0.11 per share8.18TELATELA Bio$69.30M0.58N/AN/A$0.77 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHYPRHyperfine-$44.24M-$0.56N/AN/AN/A-309.42%-57.54%-50.38%5/12/2025 (Estimated)MLSSMilestone Scientific-$6.93M-$0.07N/A∞N/A-52.01%-60.26%-40.23%N/ATELATELA Bio-$46.66M-$1.39N/AN/AN/A-60.49%-556.18%-63.13%5/8/2025 (Estimated)Latest CTCX, TELA, HYPR, and MLSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024TELATELA Bio-$0.24-$0.23+$0.01-$0.23$23.17 million$17.65 million3/17/2025Q4 2024HYPRHyperfine-$0.16-$0.14+$0.02-$0.14$2.30 million$2.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HYPRHyperfineN/A6.445.73MLSSMilestone ScientificN/A2.851.86TELATELA Bio14.222.621.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HYPRHyperfine15.03%MLSSMilestone Scientific5.79%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HYPRHyperfine29.42%MLSSMilestone Scientific24.75%TELATELA Bio6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHYPRHyperfine19077.83 million51.49 millionOptionableMLSSMilestone Scientific3077.89 million58.61 millionOptionableTELATELA Bio12039.39 million37.03 millionOptionableCTCX, TELA, HYPR, and MLSS HeadlinesRecent News About These CompaniesTELA Bio launches larger sizes of OviTex PRS for plastic and reconstructive surgeryApril 2 at 8:37 AM | pharmabiz.comTELA Bio Expands OviTex PRS Line with Larger Surgical SizesApril 2 at 8:37 AM | msn.comTela Bio announces U.S. launch of larger sizes of OviTex PRSApril 1 at 2:38 AM | markets.businessinsider.comTELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive SurgeryApril 1 at 2:38 AM | markets.businessinsider.comPerkins Capital Management Inc. Has $2.74 Million Holdings in TELA Bio, Inc. (NASDAQ:TELA)March 25, 2025 | marketbeat.comTELA BIO Earnings Results: $TELA Reports Quarterly EarningsMarch 23, 2025 | nasdaq.comTELA Bio Full Year 2024 Earnings: Revenues DisappointMarch 23, 2025 | finance.yahoo.comCanaccord Genuity Group Lowers TELA Bio (NASDAQ:TELA) Price Target to $7.00March 22, 2025 | marketbeat.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comTELA Bio (NASDAQ:TELA) Rating Lowered to Neutral at Piper SandlerMarch 22, 2025 | marketbeat.comTELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deTela Bio price target lowered to $7 from $12 at Citizens JMPMarch 21, 2025 | markets.businessinsider.comTela Bio downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comTELA Bio Shares Drop 43% After Weak Q4 Growth, High Sales TurnoverMarch 21, 2025 | finance.yahoo.comTela Bio slumps after Q4 miss as Piper Sandler downgradesMarch 21, 2025 | msn.comTELA Bio’s Earnings Call: Challenges and Optimism for 2025March 21, 2025 | tipranks.comTELA Bio (NASDAQ:TELA) Releases Earnings Results, Beats Estimates By $0.01 EPSMarch 21, 2025 | marketbeat.comTela Bio sees Q1 revenue $17M-$18M, consensus $21.05MMarch 21, 2025 | markets.businessinsider.comTELA Bio shares plunge on Q4 revenue miss, weak guidanceMarch 21, 2025 | investing.comTELA Bio sees 23-27% revenue growth for 2025 with expanded sales strategyMarch 21, 2025 | msn.comTELA Bio, Inc. (TELA) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTCX, TELA, HYPR, and MLSS Company DescriptionsCarmell NASDAQ:CTCX$0.14 +0.00 (+2.65%) As of 04/3/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Hyperfine NASDAQ:HYPR$0.69 0.00 (-0.69%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Milestone Scientific NYSE:MLSS$0.90 -0.02 (-2.17%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.TELA Bio NASDAQ:TELA$1.02 -0.15 (-12.82%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
